news
First hospitalised COVID-19 patient dosed in FSD201 treatment trial
The study will evaluate whether FSD201 is safe and of benefit to hospitalised patients with COVID-19, in combination with standard of care.
List view / Grid view
Coronavirus
news
Many people may not receive a COVID-19 vaccine until 2022
Studies show that more than a fifth of the global population, mostly in low- and middle-income countries, may have to wait until at least 2022 to receive a COVID-19 vaccine.
article
New opportunities for the global API market
Active pharmaceutical ingredients (APIs) are primary components in the manufacture of drugs, yet this global market experiences numerous challenges. Regulatory pressure, pricing arbitrages, a shift to digital manufacturing and patents for blockbuster drugs are chief among them, but the COVID-19 pandemic added a further hurdle as governments globally decided to…
news
COVID-19 challenge trials: is there a compelling ethical argument against?
Ethicist says that, should trials offer the huge benefits and low risks, he finds no compelling ethical objection to challenge trials for COVID-19 vaccines.
article
Raman spectroscopy: a useful tool in the fight against COVID-19
Raman spectroscopy has numerous applications in the pharmaceutical industry, ranging from verification of raw materials to quality control of products. This article explores how researchers are using the technique to aid our understanding of SARS-CoV-2, potentially improving detection speed and methods of analysis.
![Vials labelled 'COVID-19 Vaccine Pfizer' [Giovanni Cancemi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Pfizer-covid-19-vaccine-300x278.jpg)
![Vials labelled 'COVID-19 Vaccine Pfizer' [Giovanni Cancemi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Pfizer-covid-19-vaccine-scaled-e1607955047519.jpg)
news
FDA grants Emergency Use Authorization for Pfizer’s COVID-19 vaccine BNT162b2
The US has approved emergency use of Pfizer and BioNTech’s COVID-19 vaccine, BNT162b2, in people 16 years of age and older.
news
AstraZeneca to test combination of AZD1222 and Sputnik V vaccines
AstraZeneca will begin testing whether they can improve the efficacy of AZD1222 by combining it with the Ad26 human adenoviral vector from Russia’s Sputnik V vaccine.
article
The Editors’ views: European Pharmaceutical Review’s 2020 round-up
Junior Editors of European Pharmaceutical Review, Hannah Balfour and Victoria Rees, discuss some of the most noteworthy news and announcements from this year.
news
Pfizer’s COVID-19 vaccine data accessed in EMA cyber-attack
Pfizer and BioNTech told that documents relating to their COVID-19 vaccine approval were accessed during a cyber-attack on the European Medicines Agency (EMA).
news
Health Canada authorises emergency use of Pfizer’s COVID-19 vaccine
Canada becomes the third country to approve Pfizer and BioNTech’s mRNA COVID-19 vaccine BNT162b2 for emergency use - after UK and Bahrain.
news
AZD1222 vaccine for COVID-19 is safe and effective in Phase III trials
Interim analysis shows AZD1222 vaccine is effective at preventing COVID-19, with no severe cases or hospitalisations reported more than 21 days after first injection.
news
Supply chain challenges cause Pfizer’s COVID-19 vaccine production target to be slashed
Pfizer spokesperson reveals supply chain challenges and late clinical trial results contributed to its COVID-19 vaccine production target for 2020 being halved.
article
Could newborn stem cells revolutionise cell therapies?
In this article, Dr Jaime Shamonki, Generate Life Science’s CMO, discusses how newborn stem cells derived from umbilical cord tissue could make mesenchymal stem cells less expensive and variable to produce.
news
COVID-19 S-Trimer vaccine candidates show promise in early trials
When adjuvanted with GSK’s pandemic adjuvant system, the S-Trimer vaccine candidates induced the production of neutralising antibodies in all trial participants.
news
Contributing to ACT Accelerator could generate $466 billion for major economies, says Eurasia Group report
The report found that the 10 major economies could see a return of more than $466 billion by 2025, 12 times the total estimated cost of supporting the WHO’s Access to COVID-19 Tools (ACT) Accelerator.
